Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells

Hypoxia‐inducible factor‐1α and nuclear factor‐κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non‐small‐cell lung cancer cells

(2019) Rong Guo et al.   CANCER SCIENCE

Different sensitivities of senescent breast cancer cells to immune cell‐mediated cytotoxicity

(2019) Touko Inao et al.   CANCER SCIENCE

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

(2019) David A. Schaer et al.   CLINICAL CANCER RESEARCH

Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy

(2018) Joana M. Murad et al.   CYTOTHERAPY

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer

(2018) Ryosuke Tanino et al.   Oncotarget

Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment

(2018) Kelong Tao et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

(2018) Susanne H. Baumeister et al.   Cancer Immunology Research

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition

(2017) Li Yang et al.   Scientific Reports

NKG2D ligands mediate immunosurveillance of senescent cells

(2016) Adi Sagiv et al.   Aging-US

The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

(2016) Nan Zhang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulation of NKG2D+CD8+ T-cell-mediated antitumor immune surveillance: Identification of a novel CD28 activation-mediated, STAT3 phosphorylation-dependent mechanism

(2016) Jiemiao Hu et al.   OncoImmunology

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

(2015) Tu Nguyen-Ngoc et al.   Journal of Thoracic Oncology

Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma

(2015) Patcharee Ritprajak et al.   ORAL ONCOLOGY

Anti-apoptotic proteins on guard of melanoma cell survival

(2013) Mariusz L. Hartman et al.   CANCER LETTERS

PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells

(2013) Erin E. West et al.   JOURNAL OF CLINICAL INVESTIGATION

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2013) Luis G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

Aging, Cellular Senescence, and Cancer

(2012) Judith Campisi   Annual Review of Physiology

The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression

(2010) Jean-Philippe Coppé et al.   Annual Review of Pathology-Mechanisms of Disease

Therapy-Induced Senescence in Cancer

(2010) Jonathan A. Ewald et al.   JNCI-Journal of the National Cancer Institute

Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy

(2008) Ahmad Safa et al.   CURRENT CANCER DRUG TARGETS

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY